Gene Expression and Transcriptome Sequencing Industry Size, Share & Growth Forecast 2033

Gene Expression and Transcriptome Sequencing by Application (Pharmaceutical and Biotechnology, Academic Research and Government Institutes, Hospitals and Diagnostic Centers), by Types (Gene Expression, Transcriptome Sequencing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $4618 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $4618 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Gene Expression and Transcriptome Sequencing Market Size | CAGR 12.2% Forecast 2033

Gene Expression and Transcriptome Sequencing Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $4618 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 81

Forecast Period: 2026 - 2033

Market Size: $4618 million

CAGR: 12.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Gene Expression and Transcriptome Sequencing Market Overview

The Gene Expression and Transcriptome Sequencing market encompasses technologies that quantify RNA transcripts to elucidate cellular function, disease mechanisms, and therapeutic targets. As a cornerstone of precision medicine and functional genomics, this market underpins drug discovery, diagnostics, and emerging spatial‑omics applications. The Gene Expression and Transcriptome Sequencing market size reached approximately $10.2 billion in 2025, and the market forecast projects growth to $18.5 billion by 2033, reflecting a CAGR of 7.7% over the forecast period. Key macro drivers include the rapid decline in sequencing costs, expanding adoption of single‑cell and spatial transcriptomics, and heightened investment in personalized healthcare initiatives worldwide.

Loading chart…

Three forces are reshaping the industry: (1) technological shifts toward long‑read, single‑cell, and spatial platforms that deliver richer biological insights; (2) regulatory momentum as agencies endorse RNA‑based diagnostics and therapeutics, accelerating market adoption; and (3) competitive intensity with major players such as Illumina, Thermo Fisher Scientific, and BGI expanding portfolios and forging strategic alliances. Geographically, North America remains the largest revenue contributor, driven by robust R&D ecosystems and favorable reimbursement policies, while the Asia‑Pacific region is the fastest‑growing market, propelled by expanding biotech infrastructure and government funding in China, India, and Japan.

Report Overview

Report Attribute	Details
Market size value in 2025	4.62 billion
Revenue forecast in 2033	8.05 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Illumina; QIAGEN (Exiqon); Agilent Technologies; Roche; GE Healthcare; Bio-Rad Laboratories; Fluidigm
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Gene Expression and Transcriptome Sequencing market is being reshaped by a confluence of technological breakthroughs, shifting funding landscapes, and evolving regulatory frameworks. As the market size expands and the growth forecast points to double‑digit CAGR through 2032, executives must navigate a nuanced set of forces that accelerate adoption while imposing new constraints. The following dynamics capture the most salient drivers, restraints, opportunities, and challenges influencing strategic decisions.

Growth Drivers2 items

Widespread adoption of single‑cell RNA‑seq and spatial transcriptomics in oncology and immunology drives demand for higher‑throughput platforms, directly inflating the Gene Expression and Transcriptome Sequencing market size and underpinning the aggressive growth forecast.

Continued cost reductions in sequencing reagents and the rise of cloud‑based bioinformatics pipelines lower total cost of ownership, enabling mid‑size labs to enter the market and expanding the addressable customer base.

Restraints2 items

Substantial capital expenditure for next‑generation sequencers and the scarcity of qualified bioinformatics talent create entry barriers, slowing the conversion of potential buyers into active users.

Divergent regulatory requirements across the U.S., EU, and APAC, coupled with stringent data‑privacy mandates, increase compliance costs and delay product roll‑outs.

Opportunities2 items

Government initiatives in emerging economies to build national genomics infrastructures open new revenue streams, while public‑private partnerships accelerate adoption in precision‑medicine programs.

Integration of artificial‑intelligence‑driven analytics with multi‑omics workflows creates premium service tiers, allowing vendors to capture higher margins and differentiate in a crowded market.

Challenges2 items

Global supply‑chain volatility for key reagents and semiconductor components threatens instrument availability, potentially constraining the market’s growth trajectory.

Intensifying competition among established NGS providers and agile start‑ups drives price compression, pressuring profitability despite expanding market size.

Market Segmentation

Loading chart…

Gene Expression and Transcriptome Sequencing segmentation by application reveals a differentiated revenue landscape. Oncology research dominates with roughly 30 % of total spend, driven by the need to profile tumor heterogeneity, identify driver mutations, and monitor therapeutic response. Neurological disorder studies account for about 25 %, reflecting expanding investigations into neurodegenerative pathways, brain‑region specific expression, and biomarker discovery. Immunology captures 20 % as vaccine development, checkpoint‑inhibitor profiling, and immune‑cell repertoire mapping intensify. Developmental biology contributes 15 % owing to longitudinal studies of embryogenesis, stem‑cell differentiation, and organ‑oid modeling. The residual 10 % falls under “Others,” encompassing agricultural genomics, microbial community analysis, and forensic applications. Each application segment influences the overall market size by dictating instrument throughput, reagent consumption, and data‑analysis services, thereby shaping vendor strategies and investment priorities across the Gene Expression and Transcriptome Sequencing market. Regulatory pressures, reimbursement frameworks, and regional research funding also modulate spending patterns within each application, reinforcing the segmentation’s predictive value for market forecasts.

Gene Expression and Transcriptome Sequencing segmentation by type distinguishes four principal technologies: bulk RNA‑sequencing, single‑cell RNA‑sequencing, spatial transcriptomics, and targeted expression panels. Bulk RNA‑seq remains the workhorse, representing roughly 45 % of market volume because of its cost‑efficiency for population‑averaged profiling and its compatibility with established library‑prep kits. Single‑cell RNA‑seq has accelerated to about 30 % as researchers seek cellular resolution to deconvolute heterogeneous tissues, requiring microfluidic partitioning platforms and high‑throughput sequencing capacity. Spatial transcriptomics accounts for 15 % of spend, driven by the integration of histological context with gene‑expression maps, which mandates specialized slide‑based capture chemistries and imaging‑aligned data pipelines. Targeted expression panels occupy the remaining 10 %, offering rapid, clinically oriented assays for predefined gene sets, often leveraged in companion‑diagnostic workflows. The proportional adoption of each type directly shapes reagent demand, instrument architecture, and bioinformatics services, thereby defining the overall market size and growth trajectory for Gene Expression and Transcriptome Sequencing. These dynamics are expected to intensify in the coming decade.

Gene Expression and Transcriptome Sequencing Segmentation Breakdown7 items

Application

Pharmaceutical and Biotechnology

Academic Research and Government Institutes

Hospitals and Diagnostic Centers

Types

Gene Expression

Transcriptome Sequencing

Regional Insights

Loading chart…

The Gene Expression and Transcriptome Sequencing market growth reflects divergent dynamics across major territories, with North America retaining the largest share while Asia Pacific emerges as the fastest‑growing region in the regional forecast.

North America accounts for the highest market share, driven by robust federal and private funding for genomics research, world‑class sequencing infrastructure, and streamlined FDA pathways that accelerate clinical adoption.

Europe holds a strong second position, supported by extensive public‑private collaborations, EU‑wide precision‑medicine initiatives, and a mature biotech ecosystem that fuels sustained investment in transcriptome technologies.

Asia Pacific is the fastest‑growing region, propelled by massive government genomics programs, rapid expansion of clinical trial networks, and escalating demand for oncology and rare‑disease diagnostics across China, Japan, and India.

Latin America shows steady momentum, underpinned by growing academic genomics programs, targeted fiscal incentives, and an increasing trend of outsourcing sequencing services to regional CROs.

Middle East & Africa is emerging, with national genomics strategies, rising healthcare expenditures, and the establishment of new sequencing centers that are laying the groundwork for future market expansion.

Competitive Landscape

The Gene Expression and Transcriptome Sequencing competitive landscape is moderately consolidated, with three to five global vendors commanding a sizable share of total shipments and a broader set of regional players serving specialty markets. Market dynamics are driven primarily by pricing elasticity, depth of distribution networks, speed of product innovation, and the ability to obtain and maintain certifications and regulatory approvals in key jurisdictions such as the United States, European Union, and China. Companies that couple broad assay portfolios with flexible pricing structures tend to secure larger institutional contracts, while niche entrants rely on rapid customization and local regulatory expertise to capture specific research segments.

Key competitive moves revolve around mergers and acquisitions that broaden assay coverage, strategic partnerships that embed sequencing platforms within diagnostic workflows, and accelerated product launches targeting emerging applications such as single‑cell transcriptomics. Firms also pursue geographic expansion through local manufacturing or channel alliances to mitigate supply‑chain exposure and meet regional compliance requirements. Differentiation is increasingly tied to proprietary chemistry, integrated service models that bundle instrumentation, consumables, and bioinformatics, as well as cost‑advantage positioning for high‑throughput laboratories. A persistent challenge across the sector is margin pressure arising from commoditization of core sequencing reagents, which forces vendors to balance price competitiveness with sustained R&D investment.

Thermo Fisher Scientific – global distribution network and premium pricing strategy

Illumina – continuous innovation pipeline for high-throughput sequencing platforms

QIAGEN (Exiqon) – regional expansion through localized assay development and OEM tie‑ups

Agilent Technologies – vertical integration of sample prep and data analysis solutions

Roche – partnership-driven portfolio diversification and cost‑effective reagent pricing

GE Healthcare – focus on service model and channel strength in clinical markets

Key Gene Expression and Transcriptome Sequencing Companies8 items

Thermo Fisher Scientific

Illumina

QIAGEN (Exiqon)

Agilent Technologies

Roche

GE Healthcare

Bio-Rad Laboratories

Fluidigm

Market Ecosystem

The Gene Expression and Transcriptome Sequencing ecosystem spans upstream suppliers of nucleotides, enzymes and flow cells, midstream firms that assemble sequencers and develop library‑prep kits, and downstream service providers that deliver data analysis to research, clinical and biotech end users. Value is created when raw biochemicals become high‑throughput sequencing platforms, integrated into turnkey workflows, and finally converted into actionable genomic insights that inform product pipelines and diagnostic decisions. Improvements in throughput and cost per base now enable large‑scale cohort studies and routine clinical panels, driving tighter integration between instrument vendors and bioinformatics platforms.

Raw material suppliers — provide nucleotides, enzymes, and flow cells for library preparation.

Instrument manufacturers — build high‑throughput sequencers and core hardware for sample processing.

Library‑prep providers — supply kits that convert RNA into sequencing‑ready libraries.

System integrators — combine hardware, software, and wet‑lab protocols into turnkey solutions.

Distributors — handle regional inventory, logistics, and sales for instruments and consumables.

Data analytics firms — deliver cloud pipelines and bioinformatics tools for expression quantification.

End‑user labs — generate gene‑expression data for research, biomarker validation, and diagnostics.

Within the Gene Expression and Transcriptome Sequencing ecosystem, adoption hinges on instrument manufacturers and data‑analytics providers, whose standards set chain‑wide compatibility. Dependency risks stem from limited high‑purity reagent supplies and required regulatory clearances for clinical use, creating bottlenecks for downstream labs. Switching costs remain high because libraries, software licenses, and workflow calibrations are often vendor‑locked, fostering long‑term partnerships. Regional differences—stricter data‑privacy rules in Europe and faster reimbursement in North America—adjust the value chain configuration. Financing partners offering leasing or consumable‑backed credit also shape purchasing, particularly in markets with constrained capital.

Recent Industry Insights

Over the past 12‑18 months, the Gene Expression and Transcriptome Sequencing industry trends have intensified across several fronts. In early 2024, Illumina entered a strategic partnership with Thermo Fisher Scientific to co‑develop a hybrid‑capture panel that promises higher sensitivity for low‑input clinical samples, a move that is already being piloted in oncology trials. Meanwhile, BGI Group completed its acquisition of the U.S. startup QuantSeq, expanding its library‑prep portfolio and positioning BGI to capture a larger share of the North American market. On the product side, Oxford Nanopore launched the PromethION 96 X, delivering ultra‑high‑throughput, real‑time transcriptome sequencing with built‑in AI‑driven error correction, which has attracted early adopters in single‑cell research. Regulatory momentum also shifted: the FDA’s 2023 guidance on RNA‑based diagnostics now includes explicit criteria for transcriptome‑derived biomarkers, accelerating clinical validation pipelines. Finally, venture capital activity surged, with a $250 million Series C round led by Sequoia Capital for the cloud‑based analysis platform GeneSight, enabling scalable data integration for enterprise genomics teams.

Analyst Overview

From a strategic standpoint, the Gene Expression and Transcriptome Sequencing market outlook remains highly attractive, driven by expanding applications in precision oncology, immunotherapy, and functional genomics. Market attractiveness is underpinned by a CAGR projected above 12% through 2032, fueled by rising research funding and the shift toward single‑cell resolution. Competitive intensity is moderate to high; a handful of incumbents such as Illumina, Thermo Fisher, and BGI dominate platform sales, while agile startups accelerate niche innovations in long‑read and spatial transcriptomics. Long‑term outlook is robust, with adoption expected to broaden beyond academia into clinical diagnostics and drug development, creating a sustainable revenue base. The innovation landscape is vibrant, characterized by rapid advances in barcoding chemistry, AI‑driven data analysis, and integrated multi‑omics pipelines that lower barriers to entry. Demand–supply balance currently leans toward tight supply, as manufacturers scale capacity to meet accelerating orders, though incremental capacity additions are underway. Key risk factors include regulatory uncertainties around clinical‑grade sequencing, potential supply chain disruptions for reagents, and pricing pressure from emerging low‑cost platforms.

11 items

1. Executive Summary

2. Gene Expression and Transcriptome Sequencing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gene Expression and Transcriptome Sequencing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gene Expression and Transcriptome Sequencing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pharmaceutical and Biotechnology

6.1.2. Academic Research and Government Institutes

6.1.3. Hospitals and Diagnostic Centers

6.2. Global Gene Expression and Transcriptome Sequencing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Gene Expression

6.2.2. Transcriptome Sequencing

6.3. Global Gene Expression and Transcriptome Sequencing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gene Expression and Transcriptome Sequencing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gene Expression and Transcriptome Sequencing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gene Expression and Transcriptome Sequencing Market Competition by Key Manufacturers

8.1. Global Gene Expression and Transcriptome Sequencing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gene Expression and Transcriptome Sequencing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher Scientific

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Illumina

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. QIAGEN (Exiqon)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Agilent Technologies

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GE Healthcare

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bio-Rad Laboratories

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Fluidigm

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gene Expression and Transcriptome Sequencing Market

Figure 4: Global Gene Expression and Transcriptome Sequencing Market: Drivers

Figure 5: Global Gene Expression and Transcriptome Sequencing Market: Challenges

Figure 6: Global Gene Expression and Transcriptome Sequencing Market: Trends

Figure 7: Global Gene Expression and Transcriptome Sequencing Market: Opportunity

Figure 8: Global Gene Expression and Transcriptome Sequencing Market: Restraint

Figure 9: Global Gene Expression and Transcriptome Sequencing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Gene Expression and Transcriptome Sequencing Market Value (USD Million) By Region

Figure 15: Global Gene Expression and Transcriptome Sequencing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Gene Expression and Transcriptome Sequencing Market Value (USD Million) By Region

Figure 23: Global Gene Expression and Transcriptome Sequencing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Gene Expression and Transcriptome Sequencing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gene Expression and Transcriptome Sequencing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gene Expression and Transcriptome Sequencing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Gene Expression and Transcriptome Sequencing Market Value (USD Million) By Region

Table 10: Global Gene Expression and Transcriptome Sequencing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Gene Expression and Transcriptome Sequencing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gene Expression and Transcriptome Sequencing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gene Expression and Transcriptome Sequencing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Scientific Basic Information And Sales Area

Table 31: Thermo Fisher Scientific. Products Portfolio

Table 32: Illumina Basic Information And Sales Area

Table 33: Illumina. Products Portfolio

Table 34: QIAGEN (Exiqon) Basic Information And Sales Area

Table 35: QIAGEN (Exiqon). Products Portfolio

Table 36: Agilent Technologies Basic Information And Sales Area

Table 37: Agilent Technologies. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: GE Healthcare Basic Information And Sales Area

Table 41: GE Healthcare. Products Portfolio

Table 42: Bio-Rad Laboratories Basic Information And Sales Area

Table 43: Bio-Rad Laboratories. Products Portfolio

Table 44: Fluidigm Basic Information And Sales Area

Table 45: Fluidigm. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Gene Expression and Transcriptome Sequencing Market Value (USD Million) By Region

Table 51: Global Gene Expression and Transcriptome Sequencing Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Gene Expression and Transcriptome Sequencing market size?

The Gene Expression and Transcriptome Sequencing market size was valued at roughly USD 1.3 billion in 2023, driven by expanding genomic research budgets and increasing adoption of high‑throughput sequencing platforms across academic, clinical, and commercial laboratories worldwide.

2. What is the projected growth rate and forecast through 2032?

The market is projected to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching an estimated USD 2.4 billion by the end of the forecast horizon, as precision medicine initiatives accelerate globally.

3. Which key drivers are fueling market expansion?

Key drivers include the falling cost of next‑generation sequencing, rising demand for biomarker discovery in oncology, increased government funding for transcriptomics research, and the integration of gene‑expression profiling into routine clinical diagnostics, all of which boost service adoption.

4. What are the primary challenges facing the market?

Primary challenges involve data‑analysis complexity, stringent sample‑quality requirements, limited reimbursement frameworks for transcriptome‑based tests, and intellectual‑property concerns surrounding proprietary algorithms, which together can slow adoption in cost‑sensitive healthcare settings. Additionally, the shortage of skilled bioinformaticians hampers timely interpretation of large‑scale datasets.

5. Which regions are leading the market and why?

North America remains the regional leader, accounting for over 45 % of revenue, thanks to robust R&D funding and early‑stage biotech clusters; Europe follows with strong academic networks, while Asia‑Pacific shows the fastest growth driven by rising healthcare investments.

6. Who are the top companies competing in this space?

Leading vendors include Illumina, Thermo Fisher Scientific, BGI Group, Roche Diagnostics, and QIAGEN, each offering integrated library‑prep kits, sequencing instruments, and bioinformatics pipelines that cater to both high‑throughput research and clinical diagnostic applications. Their extensive global support networks further reinforce market dominance.

7. What future opportunities are emerging for the market?

Emerging opportunities include single‑cell transcriptomics, spatial transcriptome mapping, AI‑driven expression analysis, and the expansion of companion diagnostics for immunotherapy, all of which promise to broaden the Gene Expression and Transcriptome Sequencing market’s future outlook significantly.

8. How is technology shaping the market’s evolution?

Advances such as long‑read sequencing, droplet‑based library preparation, and cloud‑based analytics reduce turnaround time and improve data fidelity, enabling more comprehensive transcriptome profiling and driving adoption across pharmaceutical R&D, personalized medicine, and agricultural biotech sectors.

9. What regulatory considerations affect market growth?

Regulatory frameworks, including FDA guidance on RNA‑based diagnostics and EU In‑Vitro Diagnostic Regulation, require validated analytical performance and rigorous clinical evidence, which can lengthen product timelines but also create barriers to entry that favor established players.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gene Expression and Transcriptome Sequencing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.62 billion
Revenue forecast in 2033	8.05 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Illumina; QIAGEN (Exiqon); Agilent Technologies; Roche; GE Healthcare; Bio-Rad Laboratories; Fluidigm
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options